**Indication and Usage**

Semaglutide injection indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Our Semaglutide is compounded. Compounded Semaglutide **is not FDA approved**.(FDA has no way of monitoring compounding medications).

L**imitations of Use**

* Semaglutide should not be co-administered with other semaglutide-containing products or with any GLP-1 receptor agonist.
* The safety and effectiveness of Semaglutide in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
* Semaglutide has not been studied in patients with a history of pancreatitis.

**Contraindications**

Semaglutide is contraindicated in patients with a personal or family history of MTC (Medullary thyroid cancer) or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to Semaglutide and history of Pancreatitis due to Semaglutide in the past, Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide.

**Warnings and Precautions/side effects are including but not limited to:**

* Acute Pancreatitis
* Risk of Thyroid C-Cell Tumors/cancer
* Acute Gallbladder Disease
* Hypoglycemia
* Acute Kidney
* Hypersensitivity
* Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
* Heart Rate Increase
* Suicidal Behavior and Ideation

**Patient Initial \_\_\_\_\_\_\_\_\_\_**

**Adverse Reactions**

* The most common adverse reactions reported in ≥5% of patients treated with Semaglutide are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

**Drug Interactions**

* The addition of semaglutidein patients treated with insulin has not been evaluated. When initiating Semaglutide, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
* Semaglutidecauses a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy.

**Use in Specific Populations**

* **Pregnancy:**can cause fetal harm. You need to be on contraception while on treatment. When pregnancy is recognized, discontinue Semaglutide.Discontinue Semaglutide in patients at least 2 months before a planned pregnancy.
* Has to stop the treatment 8 weeks prior to any surgeries**.**

**I have read and fully understand this consent form. I understand the precautions and fully accept the risks. I hereby release River oaks Beauty and Weight loss/Bellaire Beauty Weight Loss Center and the physician/staff from all liabilities associated with this treatment plan.**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Patient/Guardian Signature Print Name**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Physician Signature Date**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Witness**